{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Wang L"],"funding":["Natural Science Foundation of China","the National major science and technology project for the prevention and treatment of AIDS and viral hepatitis","Sun Yat-Sen University Clinical Research 5010 Program","Guangzhou Municipal Science and Technology Project","Research project on degree and postgraduate education reform in Guangdong province","Young teacher training program of Sun Yat-Sen university","the Five-Year Plan of Third Affiliated Hospital of Sun Yat-Sen University"],"pagination":["162"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8976971"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["22(1)"],"pubmed_abstract":["<h4>Background</h4>The long-term prognosis of patients with hepatitis B virus-related acute-on-chronic liver failure (HBV-ACLF) is not well characterised. We assessed long-term outcomes and the associated risk factors of HBV-ACLF patients in southern China.<h4>Methods</h4>We retrospectively analysed clinical data, adverse events, and clinical endpoint events of HBV-ACLF patients treated at our department between January 2014 and December 2018.<h4>Results</h4>A total of 616 (52.3%) patients with cirrhosis and 561 (47.7%) patients without cirrhosis were included. In 973 (83%) patients, the disease was associated only with HBV, while 204 (17%) patients had two or more aetiological factors. The proportion of patients receiving antiviral treatment for HBV was low (20.3%). Further analyses indicated that patients without cirrhosis had a significantly lower 90-day liver transplantation-free mortality and higher 5-year survival rate than those with cirrhosis (59.5% vs. 27.6%; 62% vs. 36%; P < 0.05). Remarkably, self-withdrawal of nucleos(t)ide analog (NA) was an independent risk factor for short-term prognosis. Age, cirrhosis at admission, and platelet level were closely related to long-term prognosis of HBV-ACLF patients.<h4>Conclusion</h4>The proportion of HBV-ACLF patients receiving antiviral treatment is very low in south China. Cirrhosis at admission has a significant effect on both short-term and long-term prognosis. No significant improvement in the short-term prognosis of HBV-ACLF patients was observed compared with previous studies. More comprehensive access to antiviral treatment and long-term surveillance of HBV patients are key imperatives to reduce the incidence of HBV-ACLF and improve the prognosis. Trial Registration The trial was registered at ClinicalTrials.gov (CT.gov identifier: NCT04231565) on May 13, 2020: https://register.<h4>Clinicaltrials</h4>gov/prs/app/action/SelectProtocol?sid=S0009OZY&selectaction=Edit&uid=U00036P1&ts=2&cx=27seqt."],"journal":["BMC gastroenterology"],"pubmed_title":["Long-term prognosis of patients with hepatitis B virus-related acute-on-chronic liver failure: a retrospective study."],"pmcid":["PMC8976971"],"funding_grant_id":["2018009 to CX, 2020007 to LP","16ykpy40 to CX","2018JGXM04 to CX","K00006 to LP","No. 81873572 to LP , 82070611 to LP","201904010442 to CX, 202102010204 to LP","2018ZX10302204-002 to LP, 2018ZX10302205-002 to CX"],"pubmed_authors":["Li X","Luo Q","Zhang Y","Chen Y","Peng L","Xu W","Wang J","Xie C","Wang L","Chen D"],"additional_accession":[]},"is_claimable":false,"name":"Long-term prognosis of patients with hepatitis B virus-related acute-on-chronic liver failure: a retrospective study.","description":"<h4>Background</h4>The long-term prognosis of patients with hepatitis B virus-related acute-on-chronic liver failure (HBV-ACLF) is not well characterised. We assessed long-term outcomes and the associated risk factors of HBV-ACLF patients in southern China.<h4>Methods</h4>We retrospectively analysed clinical data, adverse events, and clinical endpoint events of HBV-ACLF patients treated at our department between January 2014 and December 2018.<h4>Results</h4>A total of 616 (52.3%) patients with cirrhosis and 561 (47.7%) patients without cirrhosis were included. In 973 (83%) patients, the disease was associated only with HBV, while 204 (17%) patients had two or more aetiological factors. The proportion of patients receiving antiviral treatment for HBV was low (20.3%). Further analyses indicated that patients without cirrhosis had a significantly lower 90-day liver transplantation-free mortality and higher 5-year survival rate than those with cirrhosis (59.5% vs. 27.6%; 62% vs. 36%; P < 0.05). Remarkably, self-withdrawal of nucleos(t)ide analog (NA) was an independent risk factor for short-term prognosis. Age, cirrhosis at admission, and platelet level were closely related to long-term prognosis of HBV-ACLF patients.<h4>Conclusion</h4>The proportion of HBV-ACLF patients receiving antiviral treatment is very low in south China. Cirrhosis at admission has a significant effect on both short-term and long-term prognosis. No significant improvement in the short-term prognosis of HBV-ACLF patients was observed compared with previous studies. More comprehensive access to antiviral treatment and long-term surveillance of HBV patients are key imperatives to reduce the incidence of HBV-ACLF and improve the prognosis. Trial Registration The trial was registered at ClinicalTrials.gov (CT.gov identifier: NCT04231565) on May 13, 2020: https://register.<h4>Clinicaltrials</h4>gov/prs/app/action/SelectProtocol?sid=S0009OZY&selectaction=Edit&uid=U00036P1&ts=2&cx=27seqt.","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Apr","modification":"2025-05-29T19:47:18.462Z","creation":"2025-05-29T19:47:18.462Z"},"accession":"S-EPMC8976971","cross_references":{"pubmed":["35366805"],"doi":["10.1186/s12876-022-02239-4"]}}